Gene therapy for Parkinson's: will it last? new study tracks 6 patients over time

NCT ID NCT07629115

Recruiting now Disease control Sponsor: Innopeutics Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 4 times

Summary

This study checks the long-term safety and lasting effects of a gene therapy called IPS101A in 6 people with severe Parkinson's disease who already received it in an earlier trial. Researchers will monitor side effects and measure changes in movement symptoms over time. The goal is to see if a one-time gene therapy can safely control Parkinson's for years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPS101A gene therapy
What this could lead to: If successful, this could show that a single dose of gene therapy safely controls Parkinson's symptoms for years, reducing the need for daily medications.
What could go wrong: This is a very small follow-up study with only 6 people, so results may not apply to everyone. It is also early-stage, so long-term risks or loss of effect are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE PARKINSON'S DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Severance Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.